Premium
Adjunctive Use of Cidofovir and Intravenous Immunoglobulin to Treat Invasive Adenoviral Disease in Solid Organ Transplant Recipients
Author(s) -
Permpalung Nitipong,
Mahoney Monica V.,
Alonso Carolyn D.
Publication year - 2018
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.2194
Subject(s) - cidofovir , medicine , nephrotoxicity , transplantation , discontinuation , adenovirus infection , immunology , gastroenterology , kidney , virus
Background Infections with adenoviruses (ADVs) can result in considerable mortality and morbidity in solid organ transplant (SOT) recipients. Standard therapy for ADV infections in transplant recipients is not established. At our institution, intravenous cidofovir and immunoglobulin have been used to treat disseminated or invasive ADV in SOT and hematopoietic stem cell transplant recipients. Methods A retrospective case series of SOT recipients treated with cidofovir and intravenous immunoglobulin was performed. Results Five SOT recipients (four renal and one heart transplant) with adenovirus infection were treated successfully with cidofovir and immunoglobulin. Cidofovir was discontinued after the first negative ADV viral load and resolution of clinical symptoms, given the concern for nephrotoxicity in renal transplant recipients. Renal tubular acidosis type 2 and iritis were observed in two patients receiving therapy. Conclusion Symptom resolution and a single negative ADV viral load may be indicators for cidofovir discontinuation.